LindseyCC, CarterAW, MangumS, GreeneD, RichardsonA, BrownSJ, EssaryJL, McCandlessB. A prospective, randomized, multicentered controlled trial to compare the annual glycemic and quality outcomes of patients with diabetes mellitus monitored with weekly fructosamine testing versus usual care. Diabetes Technol Ther, 2004; 6:370–377.
6.
EdelmanSV, BellJM, SerranoRB, KelemenD. Home testing of fructosamine improves glycemic control in patients with diabetes. Endocr Pract, 2001; 7:454–458.
7.
PageRC, KirkBA, FayT, WilcoxM, HoskingDJ, JeffcoateWJ. Is macrosomia associated with poor glycaemic control in diabetic pregnancy?Diabet Med, 1996; 13:170–174.
8.
VosFE, SchollumJB, CoulterCV, ManningPJ, DuffullSB, WalkerRJ. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. Nephrology (Carlton), 2012; 17:182–188.
9.
Rodino-JaneiroBK, Gonzalez-PeteiroM, Ucieda-SomozaR, Gonzalez-JuanateyJR, AlvarezE. Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy. Diabetes Metab Res Rev, 2010; 26:550–558.
10.
LuL, PuLJ, ZhangQ, WangLJ, KangS, ZhangRY, ChenQJ, WangJG, De CaterinaR, ShenWF. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis, 2009; 206:540–545.
11.
KumedaY, InabaM, ShojiS, IshimuraE, InaribaH, YabeS, OkamuraM, NishizawaY. Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin Endocrinol (Oxf), 2008; 69:556–561.
12.
LeeYH, LeeBW, ChunSW, ChaBS, LeeHC. Predictive characteristics of patients achieving glycaemic control with insulin after sulfonylurea failure. Int J Clin Pract, 2011; 65:1076–1084.
13.
YamanouchiT, TachibanaY, AkanumaH, MinodaS, ShinoharaT, MoromizatoH, MiyashitaH, AkaokaI. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol, 1992; 263:E268–E273.
14.
KimWJ, ParkCY, LeeKB, ParkSE, RheeEJ, LeeWY, OhKW, ParkSW. Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction. Diabetes Care, 2012; 35:281–286.
15.
KilpatrickES, KeeviltBG, RichmondKL, NewlandP, AddisonGM. Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. Diabet Med, 1999; 16:496–499.
16.
KimWJ, ParkCY, ParkSE, RheeEJ, LeeWY, OhKW, ParkSW, KimSW, ParkHS, KimYJ, SongSJ, AhnHY. Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes. Diabet Med, 2012; 29:1184–1190.
17.
DunganKM, BuseJB, HermanWH, ArakakiRF, JiangHH, JacobsonJG, FahrbachJL. Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. Diabetes Res Clin Pract, 2012; 96:e66–e69.
18.
LiuL, WanX, LiuJ, HuangZ, CaoX, Yanbing LiY. Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. Diabetes Technol Ther, 2012; 14:756–761.
19.
DunganKM. 1,5-Anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn, 2008; 8:9–19.
20.
McGillJB, ColeTG, NowatzkeW, HoughtonS, AmmiratiEB, GautilleT, SarnoMJ. U.S. trial of the GlycoMark assay: Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care, 2004; 27:1859–1865.
21.
MehtaSN, SchwartzN, WoodJR, SvorenBM, LaffelLM. Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls. Pediatr Diabetes, 2012; 13:278–284.
22.
KimMJ, JungHS, Hwang-BoY, ChoSW, JangHC, KimSY, ParkKS. Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetol, 2011Jun18[Epub ahead of print].
23.
DunganK, BuseJ, LargayJ. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care, 2006; 29:1214–1219.
24.
KishimotoM, YamasakiY, KubotaM, AraiK, MorishimaT, KawamoriR, KamadaT. 1,5-Anhydro-d-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care, 1995; 18:1156–1159.
25.
GotoM, Yamamoto-HondaR, ShimboT, GotoA, TerauchiY, KanazawaY, NodaM. Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests. Endocr J, 2011; 58:13–17.
26.
FestaA, WilliamsK, D'AgostinoRJr, WagenknechtLE, HaffnerSM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes, 2006; 55:1114–1120.
HuY, LiL, XuY, YuT, TongG, HuangH, BiY, WengJ, ZhuD. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission. Diabetes Care, 2011; 34:1848–1853.
29.
BuseJB, CaprioS, CefaluWT, CerielloA, Del PratoS, InzucchiSE, McLaughlinS, PhillipsGL2nd, RobertsonRP, RubinoF, KahnR, KirkmanMS. How do we define cure of diabetes?Diabetes Care, 2009; 32:2133–2135.
30.
InzucchiSE, BergenstalRM, BuseJB, DiamantM, FerranniniE, NauckM, PetersAL, TsapasA, WenderR, MatthewsDR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care, 2012; 35:1364–1379.
31.
SuwaT, OhtaA, MatsuiT, KoganeiR, KatoH, KawataT, SadaY, IshiiS, KondoA, MurakamiK, KatabamiT, TanakaY. Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM)Endocr J, 2010; 57:135–140.
32.
BeckR, SteffesM, XingD, RuedyK, MaurasN, WilsonDM, KollmanC. Diabetes Research in Children Network (DirecNet) Study Group: The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring. Pediatr Diabetes, 2011; 12:690–695.
